1.      Alphonse MP, Duong TT, Shimizu C, et al. Inositol-triphosphate 3-kinase C mediates inflammasome activation and treatment response in Kawasaki disease. J Immunol. 2016;197(9):3481–3489. doi: 10.4049/jimmunol.1600388.

2.      Benseler SM, McCrindle BW, Silverman ED, et al. Infections and Kawasaki disease: implications for coronary artery outcome. Pediatrics. 2005;116(6):e760–e766. doi: 10.1542/peds.2005-0559.

3.      Breunis WB, Davila S, Shimizu C, et al. Disruption of vascular homeostasis in patients with Kawasaki disease: involvement of vascular endothelial growth factor and angiopoietins. Arthritis Rheum. 2012;64(1):306–315. doi: 10.1002/art.33316.

4.      Burney JA, DeHaan LL, Shimizu C, et al. Temporal clustering of Kawasaki disease cases around the world. Sci Rep. 2021;11:22584. doi: 10.1038/s41598-021-01961-5.

5.      Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004;364(9433):533–544. doi: 10.1016/S0140-6736(04)16814-1.

6.      Burns JC, Herzog L, Fabri O, et al. Seasonality of Kawasaki disease: a global perspective. PLoS One. 2013;8(9):e74529. doi: 10.1371/journal.pone.0074529.

7.      Burns JC, Shimizu C, Gonzalez E, et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J Infect Dis. 2005;192(2):344–349. doi: 10.1086/430953.

8.      Carlton-Conway D, Ahluwalia R, Henry L, et al. Behaviour sequelae following acute Kawasaki disease. BMC Pediatr. 2005;5:14. doi: 10.1186/1471-2431-5-14.

9.      Dallaire F, Fortier-Morissette Z, Blais S, et al. Aspirin dose and prevention of coronary abnormalities in Kawasaki disease. Pediatrics. 2017;139(6):e20170098. doi: 10.1542/peds.2017-0098.

10.  de Graeff N, Groot N, Ozen S, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease – the SHARE initiative. Rheumatology. 2019;58(4):672–682. doi: 10.1093/rheumatology/key344.

11.  Dogan OF, Kara A, Devrim I, et al. Peripheral gangrene associated with Kawasaki disease and successful management using prostacycline analogue: a case report. Heart Surg Forum. 2007;10(1):E70–E72. doi: 10.1532/HSF98.20061151.

12.  Durongpisitkul K, Soongswang J, Laohaprasitiporn D, et al. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol. 2003;24(2):145–148. doi: 10.1007/s00246-002-0216-2.

13.  Fukazawa R, Kobayashi J, Ayusawa M, et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease. Circ J. 2020;84(8):1348–1407. doi: 10.1253/circj.CJ-19-1094

14.  Gong GW, McCrindle BW, Ching JC, et al. Arthritis presenting during the acute phase of Kawasaki disease. J Pediatr. 2006;148(6):800–805. doi: 10.1016/j.jpeds.2006.01.039.

15.  Gorelik M, Chung SA, Ardalan K, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of Kawasaki disease. Arthritis Care Res (Hoboken). 2022;74(4):538–548. doi: 10.1002/acr.24838.

16.  Jone PN, Tremoulet A, Choueiter N, et al. Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association. Circulation. 2024;150(23):e481–e500. doi: 10.1161/CIR.0000000000001295.

17.  Kawasaki T. Acute febrile mucocutaneous lymph node syndrome: clinical observation of 50 cases. Jpn J Allergy. 1967;16:178–222.

18.  Kawata N, Sakakibara H, Yoshitomi A, et al. A prospective cohort study of sensorineural hearing loss associated with Kawasaki disease. Int J Pediatr Otorhinolaryngol. 2022;163:111365 doi: 10.1016/j.ijporl.2022.111365. 

19.  Kemmotsu Y, Nakayama T, Matsuura H, et al. Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease. Pediatr Rheumatol Online J. 2011;9:28.doi: 10.1186/1546-0096-9-28.

20.  Khor CC, Davila S, Shimizu C, et al. Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease. J Med Genet. 2011;48(7):467–472. doi: 10.1136/jmg.2010.086611.

21.  Kim GB, Yu JJ, Yoon KL, et al. Medium- or higher-dose acetylsalicylic acid for acute Kawasaki disease and patient outcomes. J Pediatr. 2017;184:125–129.e1. doi: 10.1016/j.jpeds.2016.12.019.

22.  Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study). Lancet. 2012;379(9826):1613–1620. doi: 10.1016/S0140-6736(11)61930-2. 

23.  Kuo HC, Yang KD, Juo SH, et al. ITPKC single nucleotide polymorphism associated with Kawasaki disease in a Taiwanese population. PLoS One. 2011;6(4):e17370. doi: 10.1371/journal.pone.0017370.

24.  Lee JJY, Lin E, Widdifield J, et al. The long-term cardiac and noncardiac prognosis of Kawasaki disease: a systematic review. Pediatrics. 2022;149(3):e2021052564. doi: 10.1542/peds.2021-052567.

25.  Maddox RA, Holman RC, Uehara R, et al. Recurrent Kawasaki disease: USA and Japan. Pediatr Int. 2015;57(6):1116–1120. doi: 10.1111/ped.12733.

26.  McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement from the American Heart Association. Circulation. 2017;135(17):e927–e999. doi: 10.1161/CIR.0000000000000484.

27.  Menikou S, Langford PR, Levin M. Kawasaki disease: the role of immune complexes revisited. Front Immunol. 2019;10:1156. doi: 10.3389/fimmu.2019.01156.

28.  Nakamura Y, Hirose K, Yanagawa H, et al. Incidence rate of recurrent Kawasaki disease in Japan. Acta Paediatr. 1994;83(10):1061–1064. doi: 10.1111/j.1651-2227.1994.tb12986.x.

29.  Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008;40(1):35–42. doi: 10.1038/ng.2007.59

30.  Onouchi Y. The genetics of Kawasaki disease. Int J Rheum Dis. 2018;21(1):26–30. doi: 10.1111/1756-185X.13218.

31.  Orenstein JM, Shulman ST, Fox LM, et al. Three linked vasculopathic processes characterize Kawasaki disease. PLoS One. 2012;7(6):e38998. doi: 10.1371/journal.pone.0038998.

32.  Printz BF, Sleeper LA, Newburger JW, et al. Noncoronary cardiac abnormalities are associated with coronary artery dilation in acute Kawasaki disease. J Am Coll Cardiol. 2011;57(1):86–92. doi: 10.1016/j.jacc.2010.08.619.

33.  Rodo X, Ballester J, Cayan D, et al. Association of Kawasaki disease with tropospheric wind patterns. Sci Rep. 2011;1:152. doi: 10.1038/srep00152.

34.  Rowley AH. Kawasaki disease: novel insights into etiology and genetic susceptibility. Annu Rev Med. 2011;62:69–77. doi: 10.1146/annurev-med-042409-151944.

35.  Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. Arch Dis Child. 2015;100(11):1084–1088. doi: 10.1136/archdischild-2014-307536.

36.  Smith LB, Newburger JW, Burns JC. Kawasaki syndrome and the eye. Pediatr Infect Dis J. 1989;8(2):116–118.

37.  Topçu U, Sahin N, Kayabey O, et al. Retrospective evaluation of 130 cases with Kawasaki disease follow-up in a tertiary care center in Turkey: a 20-year experience. Postgrad Med. 2024;136(2):189–197. doi: 10.1080/00325481.2024.2325334.

38.  Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol. 2012;22(2):79–85. doi: 10.2188/jea.je20110131.

39.  Uehara R, Yashiro M, Nakamura Y, et al. Kawasaki disease in parents and children. Acta Paediatr. 2003;92(6):694–697. doi: 10.1080/08035320310002768.

40.  Van Anh KY, Shah S, Tremoulet AH. Hemolysis from intravenous immunoglobulin in obese patients with Kawasaki disease. Front Pediatr. 2020;8:146. doi: 10.3389/fped.2020.00146. 

41.  Yeung RS. Kawasaki disease: update on pathogenesis. Curr Opin Rheumatol. 2010;22(5):551–560. doi: 10.1097/BOR.0b013e32833cf051.

42.  Zachariah JP, Jone PN, Agbaje AO, et al. Environmental exposures and pediatric cardiology: a scientific statement from the American Heart Association. Circulation. 2024;149(20):e1165–e1175. doi: 10.1161/CIR.0000000000001234.